icon-folder.gif   Conference Reports for NaTaP  
 
  EASL - The International Liver Congress 2015
50th annual Meeting of the European
association for the Study of the Liver
Vienna, austria áapril 22-26
Back grey_arrow_rt.gif
 
 
 
Abbvie at EASL 2015 - Healthcare Economics, Clinical Trials
 
 
  EASL: High SVR Rates Despite Multiple Negative Predictors in Genotype 1 Patients Receiving Ombitasvir/Paritaprevir/r, Dasabuvir With or Without Ribavirin For 12 and 24 Weeks: Integrated Analysis of Six Phase 3 Trials - (04/24/15) the presence of 4 negative predictive factors reduced SVR rate, SVR rate was 95% or greater in patients with fewer than 4 negative predictive factors
 
EASL: Improvement in Liver Function and Non-Invasive Estimates of Liver Fibrosis 48 Weeks after Treatment With Ombitasvir/Paritaprevir/r, Dasabuvir, and Ribavirin in HCV Genotype 1 Patients With Cirrhosis - (04/24/15) post-SVR markers of HCV disease improved including all- non-ivasive estimates of liver fibrosis - FibroTest, APRI, FIB-4, FORNS Index
 
EASL: U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C - (04/24/15)
 
AASLD/2014: Interferon-Free Regimens of Ombitasvir and ABT-450/r With or Without Ribavirin in Patients With HCV Genotype 4 Infection: PEARL-I Study Results - (12/01/14)
 
EASL: Phase 3b Studies (5 Years post-treatment) to Assess Long-Term Clinical Outcomes in HCV GT1-Infected Patients Treated With Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin - (04/27/15)
 
EASL: AbbVie to Present New Data from Hepatitis C Clinical Development Program at The International Liver Congress™ 2015 - (04/22/15)
 
EASL: SAFETY OF OMBITASVIR/PARITAPREVIR/RITONAVIR PLUS DASABUVIR FOR TREATING HCV GT1 INFECTION IN PATIENTS WITH SEVERE RENAL IMPAIRMENT OR END-STAGE RENAL DISEASE: THE RUBY-I STUDY - (04/27/15)
 
EASL: OMBITASVIR/PARITAPREVIR/RITONAVIR FOR TREATMENT OF HCV GENOTYPE 1B IN JAPANESE PATIENTS WITH OR WITHOUT CIRRHOSIS: RESULTS FROM GIFT-I - (04/28/15)
 
EASL: LONG-TERM FOLLOW-UP OF TREATMENT-EMERGENT RESISTANCE-ASSOCIATED VARIANTS IN NS3, NS5A AND NS5B WITH PARITAPREVIR/r-, OMBITASVIR- AND DASABUVIR-BASED REGIMENS - (04/24/15)
 
EASL: Malachite-I Phase 3b Trial of Ombitasvir/Paritaprevir/r and Dasabuvir ± Ribavirin or Telaprevir + Peginterferon/Ribavirin in Treatment-Na´ve Adults With Hc v Genotype 1 - (04/27/15)
 
EASL: Malachite-II : Phase 3b Trial of Ombitasvir/Paritaprevir/r and Dasabuvir + Ribavirin or Telaprevir + Peginterferon/Ribavirin in Peginterferon/Ribavirin Treatment-Experienced Adults With Hcv Genotype 1- (04/24/15)
 
EASL: Implications of Baseline HCV RNA Level and Intrapatient Viral Load Variability on OBV/PTV/r + DSV 12-Week Treatment Outcomes - (04/24/15)
 
EASL: Potent Antiviral Activity of ABT-493 and ABT-530 With 3-Day Monotherapy in Patients With and Without Compensated Cirrhosis With Hepatitis C Virus (HCV) Genotype 1 Infection - (05/04/15)
 
EASL: Steady-State Pharmacokinetics and Safety of Co-administration of Pan-Genotypic Direct Acting Protease Inhibitor ABT-493 with Pan-Genotypic NS5A Inhibitor ABT-530 in Healthy Adult Subjects - (05/04/15)
 
EASL: No Significant Interaction Among Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir and Sofosbuvir - (04/27/15)
 
EASL: Pharmacokinetics of ABT-493 and ABT-530 is Similar in Healthy Caucasian, Han Chinese, and Japanese Adult Subjects - (05/04/15)
 
EASL: A Randomized, Open-Label Study to Evaluate Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir Co-Administered With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Infection and Cirrhosis (AGATE-I) - (04/23/15)
 
EASL: An Open-Label Study to Evaluate the Efficacy and Safety of Co-Formulated Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults with Chronic HCV Genotype 4 Infection in Egypt (AGATE-II) - (04/24/15)
 
HEALTHCARE ECONOMICS
 
EASL: Healthcare Costs by Stage of Liver Disease in Chronic Hepatitis C Patients in the United States - (04/27/15)
 
EASL: SVR Reduces Morbidity/Deaths by 5-10 Fold - Abbvie Analysis - Percent of Subjects Experiencing Liver Morbidity Over a Lifetime Horizon with AbbVie 3D (Abt-450/Ritonavir/Ombitasvirand Dasabuvir) Versus No treatment - (04/31/15)
 
EASL: Reduction in Annual Medical Costs with Early Treatment of HCV Using Abbvie 3D (AbT-450/Ritonavir/Ombitasvir and Dasabuvir) ± Ribavirin in the United States - (04/28/15)
 
EASL: The Value of Survival Benefits from Treating Hepatitis C at Different Fibrosis Stages with All-Oral, Interferon-Free Therapy Relative to 'Watchful Waiting' - (04/28/15)
 
EASL: Cost-Effectiveness of Treating Different Stages of Genotype 1 Hepatitis C Virus (GT1-HCV) With Viekira Pak (Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir) ± Ribavirin Compared to No Treatment in the United States - (04/31/15)
 
AASLD/2014
 
Pharmacokinetics of Cyclosporine and Tacrolimus, Following Coadministration with the Direct Acting Antiviral Combination, ABT-450/r, Ombitasvir and Dasabuvir, in Liver Transplant Patients with Genotype-1 HCV Infection- (12/22/14)
 
AASLD: HIGH SUSTAINED VIROLOGIC RESPONSE RATES IN LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HCV GENOTYPE 1 INFECTION RECEIVING ABT-450/r/OMBITASVIR + DASABUVIR PLUS RIBAVIRIN CORAL-1 Study - (11/12/14)
 
An Interferon-free Antiviral Regimen for HCV after Liver Transplantation Abbvie 3D - (11/14/14)
 
TURQUOISE-I: 94% SVR12 in HCV/HIV-1 Co-infected Patients Treated With ABT-450/r/Ombitasvir and Dasabuvir and Ribavirin - (11/12/14)